Log in

NASDAQ:DTIL - Precision BioSciences Stock Price, Forecast & News

$8.18
-0.09 (-1.09 %)
(As of 02/19/2020 04:25 AM ET)
Today's Range
$8.05
Now: $8.18
$8.45
50-Day Range
$7.96
MA: $10.55
$15.00
52-Week Range
$6.24
Now: $8.18
$23.67
Volume232,743 shs
Average Volume697,800 shs
Market Capitalization$415.44 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DTIL
CUSIPN/A
CIKN/A
Phone919-314-5512

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.88 million

Profitability

Net Income$-46,040,000.00
Net Margins-423.14%

Miscellaneous

Employees127
Market Cap$415.44 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.


Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

How were Precision BioSciences' earnings last quarter?

Precision BioSciences Inc (NASDAQ:DTIL) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.56) by $0.15. The firm earned $4.87 million during the quarter, compared to analysts' expectations of $5.25 million. Precision BioSciences had a negative net margin of 423.14% and a negative return on equity of 78.51%. View Precision BioSciences' Earnings History.

What price target have analysts set for DTIL?

6 analysts have issued 12 month target prices for Precision BioSciences' shares. Their forecasts range from $21.00 to $24.00. On average, they expect Precision BioSciences' share price to reach $22.80 in the next year. This suggests a possible upside of 178.7% from the stock's current price. View Analyst Price Targets for Precision BioSciences.

What is the consensus analysts' recommendation for Precision BioSciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Precision BioSciences.

What are Wall Street analysts saying about Precision BioSciences stock?

Here are some recent quotes from research analysts about Precision BioSciences stock:
  • 1. According to Zacks Investment Research, "Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. " (1/14/2020)
  • 2. HC Wainwright analysts commented, "Our $21 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our 13-year DCF model. Our DCF is based on: beta of 1.6, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.5%, and tax rate of 15% beginning in FY 2028. Our $21 price target remains leveraged on the outcome of for which we assign a 25% and 10% POS, respectively, given their IND-ready status. These two assets represent approximately 73% of our rNPV, i.e., $15 per share." (7/16/2019)

Has Precision BioSciences been receiving favorable news coverage?

Media stories about DTIL stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Precision BioSciences earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the company's share price in the next several days. View News Stories for Precision BioSciences.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,860,000 shares, an increase of 8.3% from the January 15th total of 2,640,000 shares. Based on an average daily trading volume, of 1,190,000 shares, the short-interest ratio is presently 2.4 days. Currently, 8.9% of the shares of the company are short sold. View Precision BioSciences' Current Options Chain.

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Alector (ALEC), Exxon Mobil (XOM), Kaleido Biosciences (KLDO), Roku (ROKU), AT&T (T) and Twilio (TWLO).

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the folowing people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 42)
  • Dr. Derek Jantz Ph.D., Co-founder, Chief Scientific Officer & Director (Age 43)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. Abid Ansari, Chief Financial Officer (Age 41)
  • Ms. Molly Lukes PHR, SHRM-CP, Director of HR

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Capital World Investors (8.00%), FMR LLC (5.18%), ArrowMark Colorado Holdings LLC (3.83%), Alliancebernstein L.P. (3.01%), Franklin Resources Inc. (2.39%) and Victory Capital Management Inc. (1.21%). Company insiders that own Precision BioSciences stock include Christopher Heery, Global Strategic Fund Venbio and Tony Dung Ling Yao. View Institutional Ownership Trends for Precision BioSciences.

Which major investors are selling Precision BioSciences stock?

DTIL stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Hamilton Lane Advisors LLC and Barclays PLC. View Insider Buying and Selling for Precision BioSciences.

Which major investors are buying Precision BioSciences stock?

DTIL stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, Alliancebernstein L.P., ArrowMark Colorado Holdings LLC, State Street Corp, Victory Capital Management Inc., Victory Capital Management Inc., Nachman Norwood & Parrott Inc and Bailard Inc.. Company insiders that have bought Precision BioSciences stock in the last two years include Christopher Heery, Global Strategic Fund Venbio and Tony Dung Ling Yao. View Insider Buying and Selling for Precision BioSciences.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $8.18.

How big of a company is Precision BioSciences?

Precision BioSciences has a market capitalization of $415.44 million and generates $10.88 million in revenue each year. Precision BioSciences employs 127 workers across the globe.View Additional Information About Precision BioSciences.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is http://www.precisionbiosciences.com/.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]


MarketBeat Community Rating for Precision BioSciences (NASDAQ DTIL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about Precision BioSciences and other stocks. Vote "Outperform" if you believe DTIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DTIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: S&P/ASX 200 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel